GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women
    Springer Science and Business Media LLC ; 2019
    In:  Breast Cancer Research and Treatment Vol. 173, No. 3 ( 2019-2), p. 657-665
    Details
    In: Breast Cancer Research and Treatment, Springer Science and Business Media LLC, Vol. 173, No. 3 ( 2019-2), p. 657-665
    Type of Medium: Online Resource
    ISSN: 0167-6806 , 1573-7217
    URL: Article
    DOI: 10.1007/s10549-018-5031-4
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2019
    detail.hit.zdb_id: 2004077-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Neutrophil lymphocyte ratio (NLR) change after systemic treatment as a predictive factor of cancer specific survival in stage IV breast cancer.
    American Society of Clinical Oncology (ASCO) ; 2015
    In:  Journal of Clinical Oncology Vol. 33, No. 28_suppl ( 2015-10-01), p. 29-29
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 33, No. 28_suppl ( 2015-10-01), p. 29-29
    Abstract: 29 Background: Inflammatory response exacerbates mechanisms linked to tumor growth and dissemination. As an index of systemic inflammatory status, neutrophil lymphocyte ratio (NLR) may be a predictive biomarker of both prognosis and response to therapy. We evaluated initial pre-treatment NLR and post-treatment NLR change to assess whether initial and change in NLR would be predictive of disease outcome in stage IV breast cancer patients. Methods: This study included 250 stage IV breast cancer patients diagnosed at Asan Medical Center between 1997 and 2012. The NLR was calculated from the differential count by dividing neutrophil percentage by lymphocyte percentage. All initial (pre-treatment) NLR was evaluated at the first visit day in Asan medical center. Post-treatment NLR was obtained at the first follow-up visit at the outpatient department after first treatment (chemotherapy first: about after 3weeks/endocrine therapy: after 3~6 months). The initial (pre-treatment) NLR was divided by quartile, and the NLR change was calculated by dividing post-treatment NLR by pre-treatment NLR. If the value was ≥ 1.2, NLR change was increased; if not, it was not changed or decreased. We evaluated prognostic value of NLR by comparison with Cancer Specific Survival (CSS). Results: When comparing pre-treatment NLR and post-treatment NLR, the NLR was increased in 85 patients (34%) and stationary or decreased in 165 patients (66%). There was no significant difference between two groups in baseline characteristics. On the other hand, in CSS, the difference between two groups are shown, but does not have statistical significance (log rank p = 0.052). The 1, 3, 5 year CSS rate was 78.8%, 35.7%, 20.5% in increased NLR group, and 87.1%, 49.3%, 26.9% in the other group. Multivariate analysis suggested that increased NLR change (Post/Pre NLR ≥ 1.2) had statistical significance as prognostic factor of stage IV breast cancer patients after treatment (HR = 1.750, 95% CI 1.130-2.709, p-value = 0.012). Conclusions: After start of treatment, increased NLR can be correlated with poor cancer specific survival in stage IV breast cancer. The NLR change might be an index of response of systemic treatment.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/jco.2015.33.28_suppl.29
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2015
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Abstract P6-10-12: Metformin increases survival in hormone receptor-positive, Her2-positive breast cancer patients with diabetes
    American Association for Cancer Research (AACR) ; 2015
    In:  Cancer Research Vol. 75, No. 9_Supplement ( 2015-05-01), p. P6-10-12-P6-10-12
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 75, No. 9_Supplement ( 2015-05-01), p. P6-10-12-P6-10-12
    Abstract: Purpose Metformin use has recently been observed to decrease both the rate and mortality of breast cancer. Our study was aim to determine whether metformin use is associated with survival in diabetic breast cancer patients by breast cancer subtype and systemic treatment Patients and Methods Data from the Asan Medical Center Breast Cancer Database from 1997 to 2007 were analyzed. The study cohort comprised 6,967 nondiabetic patients, 202 diabetic patients treated with metformin, and 184 diabetic patients that did not receive metformin. Patients who were divided into three groups by diabetes status and metformin use were also divided into four subgroups by hormone receptor and HER2-neu status. Results In Kaplan-Meier analysis, the metformin group had a significantly better overall and cancer specific survival outcome compared with non metformin diabetic group (P & lt;0.005 for both). There was no difference in survival between the nondiabetic and metformin groups. In multivariate analysis, Compared with metformin group, patients who did not receive metformin tended to have a higher risk of metastasis with HR 5.37 (95%CI, 1.88 to 15.28) and breast cancer death with HR 6.51 (95% CI, 1.88 to 15.28) on the hormone receptor-positive and Her2-negative breast cancer. The significant survival benefit of metformin observed in diabetic patients who received chemotherapy and endocrine therapy (HR for DFS 2.14; 95% CI 1.14 to 4.04) was not seen in diabetic patients who did not receive these treatments. Conclusion Patients receiving metformin treatment when breast cancer diagnosis show a better prognosis only if they have hormone receptor-positive, HER2-positive tumors. Metformin treatment might provide a survival benefit when added to systemic therapy in diabetic patients. Citation Format: Hee Jeong Kim, Hyun Wook Kwon, Jong Won Lee, Sae Byul Lee, Hee Seung Park, Sei Hyun Ahn, Hae Na Shin. Metformin increases survival in hormone receptor-positive, Her2-positive breast cancer patients with diabetes [abstract] . In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P6-10-12.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/1538-7445.SABCS14-P6-10-12
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2015
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy
    Elsevier BV ; 2018
    In:  Clinical Breast Cancer Vol. 18, No. 5 ( 2018-10), p. e1165-e1172
    Details
    In: Clinical Breast Cancer, Elsevier BV, Vol. 18, No. 5 ( 2018-10), p. e1165-e1172
    Type of Medium: Online Resource
    ISSN: 1526-8209
    URL: Article
    DOI: 10.1016/j.clbc.2018.04.008
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2018
    detail.hit.zdb_id: 2175989-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Change in neutrophil-lymphocyte ratio after initiation of chemotherapy can be a prognostic indicator in de novo stage IV breast cancer patients.
    American Society of Clinical Oncology (ASCO) ; 2019
    In:  Journal of Global Oncology Vol. 5, No. suppl ( 2019-10-07), p. 70-70
    Details
    In: Journal of Global Oncology, American Society of Clinical Oncology (ASCO), Vol. 5, No. suppl ( 2019-10-07), p. 70-70
    Abstract: 70 Background: The de novo stage IV breast cancer has poor prognosis, predicting response to treatment in the affected patients is difficult. We investigated whether the initial neutrophil to lymphocyte ratio (NLR) at diagnosis and NLR change after the first palliative chemotherapy cycle can be a prognostic indicators. Methods: We retrospectively reviewed 218 de novo stage IV breast cancer patients with available NLR values who underwent palliative chemotherapy as an initial treatment. We analyzed cancer specific survival (CSS) according to initial NLR (iNLR), NLR change after the first chemotherapy cycle (ΔNLR), and a combination of these two. Results: The mean patient age was 47.2 years; the median follow-up period was 29.8 months. The mean iNLR and ΔNLR values were 2.83 ± 2.19 and 0.39 ± 3.74, retrospectively, amd were used as cut off points. There was no significant difference between low and high iNLR groups (p = 0.431); however, there was a significant correlation between ΔNLR and CSS (p = 0.031). The 1-, 3-, and 5- year CSS rates of patients in the increased ΔNLR group were significantly lower than those of patients in the stationary or decreased group. (78.4%, 35.4%, 20.8% vs 88.9%, 52.6%, 27.1%; p = 0.031). Multivariate analysis suggested that ΔNLR was an independent prognostic factor (hazard ratio (HR) = 1.748, 95% confidence interval (CI) = 1.084 - 2.818). The analysis of the combination of iNLR and ΔNLR showed that patients in the high iNLR and increased ΔNLR group had poorer prognosis than those in the low iNLR and stationary or decreased ΔNLR group (HR = 4.294, 95% CI = 1.586 - 11.629). Conclusions: Initial NLR alone was not a prognostic indicator among de novo stage IV breast cancer patients. However, patients with increased NLR after palliative chemotherapy exhibited worse CSS. Patients with high initial NLR and increased NLR after treatment might be a non responder to treatment.
    Type of Medium: Online Resource
    ISSN: 2378-9506
    URL: Article
    DOI: 10.1200/JGO.2019.5.suppl.70
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2019
    detail.hit.zdb_id: 3018917-2
    detail.hit.zdb_id: 2840981-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...